Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

Sanofi secures exclusive rights to develop plozasiran in Greater China, enhancing treatment options for hypertriglyceridemia ...

Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory ...

Regeneron-partnered Dupixent, the crown jewel of Sanofi’s commercial portfolio, continued to impress with 21.1% sales growth ...

For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.

Sanofi reports strong Q2 2025 growth with innovative launches like Dupixent and strategic acquisitions boosting sales.

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

Shares of Regeneron Pharmaceuticals were rising Friday after the biopharmaceutical company’s revenue and earnings comfortably ...

By Bhanvi Satija (Reuters) -Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it ...

Sanofi India's demerged entity, Sanofi Consumer Healthcare India, has reported a 28% year-on-year increase in Q2 revenue at ...

Sanofi Consumer Healthcare India reports ₹220 crore revenue, ₹60 crore profit, driven by exports, product launches, and ...